
Please try another search
Investing.com - Guggenheim raised its price target on Cidara Therapeutics (NASDAQ:CDTX) to $69.00 from $68.00 on Wednesday, while maintaining a Buy rating on the stock. The company, now valued at...
SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC)...
LONDON - Contract research organization hVIVO PLC (AIM:HVO) announced Monday that its client Cidara Therapeutics (NASDAQ:CDTX) has achieved positive topline results in a Phase 2b field study for...
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Cidara) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate...
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Cidara) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate...
Cidara Therapeutics, Inc. (NASDAQ:CDTX), currently valued at $615 million, announced Tuesday that it has suspended and terminated its at-the-market (ATM) prospectus related to the sale of its common...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review